Chemomab Therapeutics Ltd
NASDAQ:CMMB
Chemomab Therapeutics Ltd
Operating Income
Chemomab Therapeutics Ltd
Operating Income Peer Comparison
Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors
Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Chemomab Therapeutics Ltd
NASDAQ:CMMB
|
Operating Income
-$25.5m
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Collplant Biotechnologies Ltd
NASDAQ:CLGN
|
Operating Income
-$6.6m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
N/A
|
|
Kamada Ltd
NASDAQ:KMDA
|
Operating Income
$10.1m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
11%
|
|
Urogen Pharma Ltd
NASDAQ:URGN
|
Operating Income
-$65.5m
|
CAGR 3-Years
20%
|
CAGR 5-Years
3%
|
CAGR 10-Years
N/A
|
|
Entera Bio Ltd
NASDAQ:ENTX
|
Operating Income
-$8.9m
|
CAGR 3-Years
7%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
B
|
Bonus Biogroup Ltd
TASE:BONS
|
Operating Income
-₪32.9m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
-13%
|
See Also
What is Chemomab Therapeutics Ltd's Operating Income?
Operating Income
-25.5m
USD
Based on the financial report for Dec 31, 2023, Chemomab Therapeutics Ltd's Operating Income amounts to -25.5m USD.
What is Chemomab Therapeutics Ltd's Operating Income growth rate?
Operating Income CAGR 3Y
-32%
Over the last year, the Operating Income growth was 11%. The average annual Operating Income growth rates for Chemomab Therapeutics Ltd have been -32% over the past three years .